Solventum (NYSE: SOLV) announces it has entered into a definitive agreement to acquire Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care for $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones. Founded in 2013, Acera has developed and commercialized innovative synthetic treatment options for soft tissue repair, leveraging a proprietary electrospinning technology platform. The company’s leading Restrata® products are currently available in the U.S. and used to treat hard-to-heal, complex wounds in acute care settings.
Read the full article: Solventum Announces Agreement to Acquire Acera Surgical //
Source: https://www.prnewswire.com/news-releases/solventum-announces-agreement-to-acquire-acera-surgical-302621156.html